Sort
10,766 grants matching “checkpoint inhibitor”
Regulation of the cell cycle by SCF and APC/C ubiquitin ligases
$456,030Michele Pagano · New York University School Of Medicine · R01 · FY2011 · GM
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
$455,881Kavindra Nath · University Of Pennsylvania · R01 · FY2024 · CA
Targeting Posttranslational Modifications in Breast Carcinogenesis
$455,680Yong Wan · Emory University · R01 · FY2025 · CA
Determinants of immunotherapy response in NASH-Hepatocellular carcinoma
$455,518Josep M Llovet · Icahn School Of Medicine At Mount Sinai · R01 · FY2024 · CA
Novel Roles of TAZ and YAP in DNA Damage Repair with 3D Genome Organization and the Therapeutic Resistance in Glioblastoma
$455,465Krishna Pl Bhat · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · NS
Identifying and targeting neoantigens in aggressive salivary carcinomas
$455,430Luc Gordon Trang Morris · Sloan-Kettering Inst Can Research · R01 · FY2022 · DE
An innate immune checkpoint in cancer immunotherapy
$455,406Carla Rothlin · Yale University · R01 · FY2017 · CA
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
$455,401Michael Korrer · Vanderbilt University Medical Center · R01 · FY2021 · DE
Regulation of Tumor Immunogenicity in Glioblastoma
$455,315Sze Chun Winson Ho · University Of California, San Francisco · R01 · FY2025 · NS
Regulation of Tumor Immunogenicity in Glioblastoma
$455,315Sze Chun Winson Ho · University Of California, San Francisco · R01 · FY2023 · NS
Novel immune suppressive activities of Fas/CD95 in triple negative breast cancer
$455,145Marcus E Peter · Northwestern University At Chicago · R01 · FY2024 · CA
Chitinase-3-like-1 mediated immunosuppression in Glioblastoma
$454,876Baoli Hu · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
RasGRP3 and Protein Kinase D as therapeutic targets for Uveal Melanoma
$454,865Xu Chen · University Of California, San Francisco · R01 · FY2025 · CA
Post-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinoma
$454,783Markus Schober · New York University School Of Medicine · R01 · FY2023 · CA
RasGRP3 and Protein Kinase D as therapeutic targets for Uveal Melanoma
$454,716Xu Chen · University Of California, San Francisco · R01 · FY2023 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy
$454,633Song Li · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy
$454,633Song Li · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · CA
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
$454,625Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2024 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma
$454,526Suzanne Lentzsch · Columbia University Health Sciences · R01 · FY2024 · CA
E PROTEIN AND B CELL DIFFERENTIATION
$454,510Cornelis Murre · University Of California, San Diego · R37 · FY2007 · CA
LKB1/AMPK Signaling and Peutz-Jeghers Syndrome
$454,494Lewis C Cantley · Brigham And Women'S Hospital · P01 · FY2011 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$454,473Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
A Novel Adenoviral-Permissive, Immunocompetent Hamster Model to Evaluate Oncolytic Adenoviral Therapy for Glioblastoma
$454,473Frederick F Lang · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Immunostimulatory Nanocarrier for Breast Cancer Immunochemotherapy
$454,390Song Li · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · CA
Contribution of Myeloid-Derived Suppressor Cells to Neuro-Inflammatory Alterations and Disease Progression in Glioblastoma
$454,255Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R35 · FY2022 · NS